Abstract
Informed consent is a requirement for medical research. Obtaining consent can be complex in patients with severe psychiatric disorders, often leading to their exclusion from study participation. Here, we discuss a case involving a patient with clozapine-resistant schizophrenia, highlighting the different perspectives of caregivers and physician-researchers, with an emphasis on decision-making capacity. The case illustrates the complexity of informed consent in this population, including the challenges in assessing decision-making capacity, ethical dilemmas, and potential improvements.
We conclude that improving existing standardized assessment tools, promoting inclusive approaches to research participation, and supporting patient representation in decision-making processes can contribute to the quality and integrity of medical research involving individuals with the most severe forms of psychiatric disorders.
We conclude that improving existing standardized assessment tools, promoting inclusive approaches to research participation, and supporting patient representation in decision-making processes can contribute to the quality and integrity of medical research involving individuals with the most severe forms of psychiatric disorders.
| Translated title of the contribution | Study participation in clozapine-resistant psychosis: a case study on decision-making capacity |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 443-446 |
| Number of pages | 4 |
| Journal | Tijdschrift voor psychiatrie |
| Volume | 66 |
| Issue number | 8 |
| Publication status | Published - Oct 2024 |